(NTLA) Intellia Therapeutics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NTLA) Intellia Therapeutics, Inc. Complete Analysis Pack
Intellia Therapeutics: Business Model Canvas at a Glance
Unlock the full strategic blueprint behind Intellia Therapeutics, Inc.’s business model. This concise Business Model Canvas reveals how the company creates value, partners for innovation, and positions itself in the fast-moving biotech landscape. Ideal for investors, analysts, and strategists who want actionable insight—get the full version today.
Partnerships
Novartis hematopoietic stem cell collaboration
Novartis Institutes for BioMedical Research is Intellia Therapeutics, Inc.'s named partner for engineering hematopoietic stem cells in sickle cell disease. The deal backs ex vivo CRISPR/Cas9 work in blood disorders, a market tied to about 100,000 people in the U.S. and millions worldwide with sickle cell disease.
Regeneron hemophilia co-development
Regeneron Pharmaceuticals is Intellia Therapeutics, Inc.'s key co-development partner for liver-directed in vivo gene editing, with the alliance aimed at hemophilia A and hemophilia B programs. The deal structure supports a 50/50 split on development economics, strengthening Intellia's pipeline while lowering funding risk across these two major blood-disorder targets.
Ospedale San Raffaele clinical research
Ospedale San Raffaele is listed as a collaboration partner for Intellia Therapeutics, Inc., supporting genome-editing research and translational work. The tie adds clinical and academic depth to Intellia Therapeutics, Inc.’s pipeline, helping move programs from lab data toward patient-focused studies.
SparingVision ocular alliance
Intellia Therapeutics, Inc. and SparingVision SAS formed a strategic alliance to develop novel genomic medicines for ocular disease, extending CRISPR/Cas9 beyond Intellia Therapeutics, Inc.'s liver and blood focus. Public filings do not disclose deal value or program spend, so the key signal is platform expansion into a new, high-value eye-therapy area.
- Expands CRISPR/Cas9 into ocular disease
- Partners with SparingVision SAS
- Deal terms not publicly disclosed
- Broadens Intellia Therapeutics, Inc.'s platform reach
Academic and clinical site network
Intellia Therapeutics, Inc. depends on academic and clinical site partners to run its gene-editing trials, especially in rare disease and oncology, where patient pools are small and site expertise matters. These centers handle enrollment, sample collection, and protocol execution, which directly shapes trial speed and data quality.
In 2025, this network supported Intellia’s multi-site clinical work across lead programs like NTLA-2001 and NTLA-2002, helping the Company move studies through specialized hospitals and research centers with the right lab and dosing infrastructure.
- Drives patient enrollment
- Supports data collection
- Enables complex execution
- Critical in rare disease
- Critical in oncology
Intellia’s Key Partnerships Power CRISPR Expansion Across Three Fronts
Key partnerships center on Novartis, Regeneron, SparingVision SAS, and hospital research sites. In 2025, these links supported NTLA-2001 and NTLA-2002 and helped Intellia Therapeutics, Inc. spread CRISPR/Cas9 across blood, liver, and eye programs while sharing clinical and funding risk.
| Partner | Role |
|---|---|
| Novartis | Ex vivo blood editing |
| Regeneron | In vivo liver programs |
| SparingVision SAS | Eye disease expansion |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Intellia Therapeutics, Inc. outlining its gene-editing strategy, partners, revenues, and value creation.
Customizable Excel Spreadsheet
Quickly shows how Intellia Therapeutics relieves unmet genetic disease pain points with a clear, editable business model snapshot.
Reference Sources
Provides a credible source trail for Intellia Therapeutics, Inc. that helps verify assumptions fast and supports smarter due diligence.
Activities
CRISPR/Cas9 genome editing R&D
CRISPR/Cas9 genome editing R&D is Intellia Therapeutics, Inc.'s core activity, covering target selection, guide design, and editing optimization for in vivo and ex vivo programs. In 2025, the company kept its R&D spend near the center of the model, with CRISPR-based platform work supporting a pipeline led by NTLA-2001 and NTLA-2002.
Clinical development of NTLA-2001 and NTLA-2002
Intellia Therapeutics, Inc. advances NTLA-2001 for transthyretin amyloidosis in Phase 1 and NTLA-2002 for hereditary angioedema, making clinical development the core activity that tests in vivo CRISPR editing in patients. These programs are the key proof points for clinical validation, with NTLA-2001 showing dose-linked transthyretin reductions and NTLA-2002 built to cut annual HAE attack rates after a single treatment.
Liver-focused therapeutic pipeline advancement
Intellia Therapeutics advances four liver-directed programs: hemophilia A, hemophilia B, hyperoxaluria type 1, and alpha-1 antitrypsin deficiency. Liver delivery is the core platform theme, linking discovery work to translational and clinical milestones across these 4 targets.
Ex vivo cell therapy engineering
Intellia Therapeutics, Inc. uses ex vivo cell therapy engineering to edit cells outside the body and build next-gen cell medicines. NTLA-5001 is its ex vivo candidate for acute myeloid leukemia, while broader programs target oncology and autoimmune disease, extending the platform into cell-based medicine.
- NTLA-5001 targets acute myeloid leukemia
- Engineered cells expand oncology reach
- Autoimmune programs widen the platform
Regulatory, CMC, and safety operations
Intellia Therapeutics, Inc. runs manufacturing, quality, and regulatory work for investigational medicines so its gene-editing programs can support IND filings and move into trials. It also tracks safety and biomarker data in clinical studies, which helps decide dose, risk, and next-step progression.
- Supports IND and trial readiness
- Oversees CMC and quality controls
- Monitors safety and biomarkers
Intellia’s 2025 CRISPR Pipeline: Liver Programs and Clinical Catalysts
Intellia Therapeutics, Inc. focuses on CRISPR/Cas9 R&D, with target design, editing optimization, and liver delivery driving 2025 work across 4 liver-directed programs and ex vivo cell therapy. Clinical development is the main proof point, led by NTLA-2001 and NTLA-2002, plus NTLA-5001 for acute myeloid leukemia.
| Key activity | 2025 focus |
|---|---|
| CRISPR R&D | 4 liver programs |
| Clinical testing | NTLA-2001, NTLA-2002 |
| Ex vivo engineering | NTLA-5001 |
Full Document Unlocks After Purchase
Business Model Canvas
The Intellia Therapeutics, Inc. Business Model Canvas preview shown here is the exact document you’ll receive after purchase. It’s not a sample or mockup—what you see is the real file, formatted the same way in full. Once you buy, you’ll get instant access to this complete, ready-to-use document.
Resources
CRISPR/Cas9 platform
Intellia Therapeutics’ CRISPR/Cas9 platform is its core asset, enabling targeted genome editing for in vivo and ex vivo therapies. As of 2026, it supports multiple clinical programs, including two late-stage in vivo candidates, and remains the main driver of the Company Name’s research spend and pipeline value.
Clinical pipeline assets
Intellia Therapeutics, Inc.'s main key resources are its clinical pipeline assets, led by NTLA-2001, NTLA-2002, and NTLA-5001, plus liver-focused programs in hemophilia, hyperoxaluria type 1, and alpha-1 antitrypsin deficiency. These programs are the main value-creation engine and set the company’s near-term R&D focus, with the lead in vivo assets already in advanced clinical testing.
Patent estate and licenses
Intellia’s patent estate and licenses are a core moat: the Company builds its CRISPR, delivery, and program-specific IP through licensing and collaboration deals, including its key partnerships with Regeneron and AstraZeneca. These rights shape what it can commercialize and help protect its pipeline from copycat entry.
Scientific and clinical expertise
Intellia Therapeutics, Inc. relies on scarce gene-editing, translational, and clinical development talent to validate targets, design trials, and assess safety. In biotech, human capital is a core asset, and Intellia’s execution depends on keeping this expertise across its clinical pipeline.
- Expert team drives target validation
- Clinical talent supports safety review
Cambridge headquarters
Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, and its 2025 filing shows the site supports corporate, research, and operations work. Being in the Cambridge biotech hub helps Intellia tap deep talent and nearby partners fast.
- Cambridge, Massachusetts HQ
- Supports core functions
- Built for biotech access
Intellia’s CRISPR Platform Drives Its Core Gene-Editing Edge
Intellia Therapeutics, Inc.’s key resources are its CRISPR/Cas9 platform, 3 named clinical assets, and patent and license rights that support in vivo and ex vivo editing. Its Cambridge, Massachusetts base also gives it access to biotech talent and partners, which matters because execution depends on scarce gene-editing and clinical expertise.
| Resource | Data |
|---|---|
| Clinical assets | 3 programs |
| Late-stage in vivo | 2 candidates |
| HQ | Cambridge, MA |
Value Propositions
Potential one-time gene editing
Intellia Therapeutics, Inc. targets disease at the DNA level, aiming to turn a lifelong therapy into a one-time edit. In NTLA-2001, a single infusion cut serum transthyretin by up to 91%, showing the core value: durable control without chronic dosing.
Liver-directed in vivo delivery
Intellia Therapeutics, Inc. uses liver-directed in vivo delivery across 3 core programs, because the liver is the main source of many secreted proteins and a key site for metabolic disease control. This approach opens rare-disease targets at scale, from transthyretin amyloidosis to hereditary angioedema and alpha-1 antitrypsin deficiency.
Rare disease focus
Intellia Therapeutics, Inc. focuses on rare genetic diseases with high unmet need, including transthyretin amyloidosis, hereditary angioedema, hemophilia, hyperoxaluria type 1, and alpha-1 antitrypsin deficiency. These markets are small but medically urgent; hereditary angioedema affects about 1 in 50,000 people, and patients and physicians value disease-modifying options, not just symptom control.
Ex vivo and engineered cell therapies
Intellia’s ex vivo and engineered cell therapy work, led by NTLA-5001 in AML, broadens the platform beyond in vivo editing and adds shots on goal in oncology and autoimmune disease. This matters because one platform can now serve both direct body editing and engineered cells, widening future licensing and pipeline value.
- NTLA-5001 extends platform reach
- Supports oncology optionality
- Can expand into autoimmune disease
Partnerable genome-editing platform
Intellia Therapeutics, Inc.’s genome-editing platform is built for partnerships: larger biotech and pharma companies can tap its CRISPR/Cas9 know-how and therapeutic design to speed platform licensing and co-development. That matters because Intellia already has major pharma ties, including Regeneron and Novartis, showing the platform can scale beyond one asset.
- CRISPR/Cas9 access for partners
- Supports licensing and co-development
- Proven with major pharma collaborations
Intellia’s one-dose gene editing cuts TTR by up to 91%
Intellia Therapeutics, Inc. sells durable gene editing: a single in vivo dose can cut serum transthyretin by up to 91% in NTLA-2001, reducing chronic treatment need. Its liver-directed platform also targets rare genetic diseases, where hereditary angioedema affects about 1 in 50,000 people.
| Value driver | Data |
|---|---|
| NTLA-2001 | Up to 91% TTR reduction |
| Core in vivo programs | 3 |
| HAE prevalence | ~1 in 50,000 |
Customer Relationships
Managed pharma collaborations
Intellia Therapeutics, Inc. manages long-term B2B collaborations with four named partner groups: Novartis, Regeneron, SparingVision, and academic partners. These ties use joint planning, data sharing, and milestone tracking, which helps Intellia share R&D risk and keep partner-funded work tied to program progress.
Clinical trial participant support
Intellia Therapeutics, Inc. supports clinical trial participants through trial centers and investigators, with informed consent, site help, and ongoing safety follow-up built into each study. In rare-disease trials, where patient pools are small and retention matters, trust and clear communication are central to keeping patients engaged and reporting safety data on time.
Key opinion leader engagement
Intellia Therapeutics, Inc. must stay close to hematology, hepatology, and rare-disease key opinion leaders because they shape trial design, endpoint choices, and real-world adoption for its CRISPR platform. This matters more now: Intellia had 2 late-stage in vivo programs in 2025, so scientific trust from top specialists can speed investigator buy-in and patient referral.
Regulatory and medical dialogue
Intellia Therapeutics, Inc. relies on constant dialogue with regulators and physicians to keep gene-editing trials on track, review safety signals fast, and shape future product labeling. In a field where FDA and other agencies demand deep follow-up on off-target risk and durability, relationship management is as critical as the science.
- Supports trial approvals
- Speeds safety review
- Builds clinician trust
- Improves future positioning
Investor and stakeholder communication
As a public biotech, Intellia Therapeutics keeps investors and analysts informed through 4 quarterly earnings calls, 4 Form 10-Q filings, 1 Form 10-K, and regular corporate updates. That steady cadence helps support financing access and market confidence while it advances its CRISPR pipeline.
- 4 quarterly earnings calls
- 4 Form 10-Q filings
- 1 annual Form 10-K
- Supports financing and trust
Intellia’s 2025 trials rely on trust across patients, partners, and regulators
Intellia Therapeutics, Inc. keeps customer ties centered on partner, patient, clinician, and regulator trust. In 2025, 2 late-stage in vivo programs made these relationships key to trial speed, safety review, and future adoption.
| Customer group | Relationship focus |
|---|---|
| Partners | Joint planning and milestone tracking |
| Patients | Consent, support, safety follow-up |
| Key opinion leaders | Trial design and referral |
Channels
Clinical trial sites
Intellia Therapeutics, Inc. uses investigational trial centers as the main channel for its clinical programs, including Phase 3 studies in 2025. These sites are where patients access treatment, and they also produce the efficacy and safety data that drive each program forward.
Pharma partnership agreements
Pharma partnership agreements are a key channel for Intellia Therapeutics, Inc. to push programs like NTLA-2001 and NTLA-2002 beyond its own lab and clinical capacity. Partners add development, translational, and commercialization support, so Intellia can scale with one major alliance instead of funding every step alone.
Scientific publications and congresses
Intellia Therapeutics, Inc. uses peer-reviewed papers and congress presentations to share pipeline data from its in vivo CRISPR/Cas9 programs, including NTLA-2001 and NTLA-2002. For first-in-class therapies, this matters because repeated Phase 1/2 updates at major medical meetings help build trust with clinicians, scientists, and investors.
Corporate website and investor relations
Intellia Therapeutics, Inc. uses its corporate website and investor relations pages to post pipeline and company updates, reaching shareholders, partners, and prospective recruits with the same message. This channel supports transparency and helps shape corporate positioning through timely SEC filings, earnings materials, and program milestones.
- Shares pipeline updates fast
- Reaches investors and recruits
- Supports trust and positioning
Regulatory filings and medical communications
Intellia Therapeutics, Inc. uses SEC filings and medical communications to move its pipeline, sharing trial readouts, safety updates, and corporate guidance. As a Nasdaq-listed biotech, it must keep investors and physicians updated through 10-K, 10-Q, 8-K, press releases, and congress presentations; in 2025, that channel stays central for its 2 lead in vivo CRISPR programs.
- Required for public biotech disclosure
- Shares clinical and corporate updates
- Supports 2 lead in vivo programs
Intellia’s Core Channels Power Trials, Partnerships, and Investor Updates
Intellia Therapeutics, Inc. relies on 2 main in vivo CRISPR programs, NTLA-2001 and NTLA-2002, and their trial sites are the core channel for patient access and data capture. Pharma partnerships extend reach beyond its own labs, while SEC filings, press releases, the website, and medical congresses keep investors and physicians updated.
| Channel | Role |
|---|---|
| Trial sites | Patient access and data |
| Pharma partners | Scale development |
| SEC and congress | Disclose updates |
Customer Segments
Rare disease patients
Intellia Therapeutics, Inc. targets rare disease patients with transthyretin amyloidosis, hereditary angioedema, hemophilia A and B, hyperoxaluria type 1, and alpha-1 antitrypsin deficiency. These groups are small but severe; for example, hereditary angioedema affects about 1 in 50,000 people, and all face high unmet need.
They are the core clinical target for Intellia Therapeutics, Inc. in vivo programs, where one-time gene editing aims to treat the disease at its source rather than manage symptoms long term.
Oncology patients
Oncology patients are a distinct, high-complexity segment for Intellia Therapeutics, Inc., because NTLA-5001 is built for acute myeloid leukemia and the company also cites engineered cell therapies for cancer. Acute myeloid leukemia caused about 20,800 new U.S. cases and 11,200 deaths in 2024, showing the size and severity of the need.
Autoimmune disorder patients
Autoimmune disorder patients are a longer-term segment for Intellia Therapeutics, Inc., where engineered cell therapy is still earlier stage than its liver programs. More than 80 autoimmune diseases are known, so this expands the platform beyond liver editing and opens a much wider addressable market.
Pharmaceutical and biotech partners
Pharmaceutical and biotech partners are a core B2B customer segment for Intellia Therapeutics, Inc., with Novartis, Regeneron, and SparingVision seeking platform access, co-development, and translational know-how. Intellia’s Novartis deal includes up to $1.7 billion in milestones, showing how partner demand can scale beyond one-off research.
- Partners buy access, data, and development speed.
These collaborations help de-risk programs and expand reach beyond Intellia Therapeutics, Inc.’s in-house pipeline.
Specialist physicians and treatment centers
Hematologists, hepatologists, and rare-disease specialists are Intellia Therapeutics, Inc. key clinical customers and gatekeepers. They spot eligible patients for CRISPR trials across rare diseases that affect about 300 million people worldwide, and their referral habits will shape future adoption in commercial use.
- They identify patients fast.
- They drive trial enrollment and uptake.
Intellia Targets Rare Diseases with Big Pharma Backing
Intellia Therapeutics, Inc. focuses on rare-disease patients with high unmet need, especially TTR amyloidosis, HAE, hemophilia, HT1, and AATD, plus oncology and autoimmune patients for earlier-stage cell therapy. It also sells to pharma partners like Novartis and Regeneron, while hematologists and hepatologists act as referral gatekeepers.
| Segment | Data |
|---|---|
| HAE | ~1 in 50,000 |
| AML | 20,800 U.S. cases, 11,200 deaths |
| Partners | Up to $1.7B Novartis milestones |
Cost Structure
Research and development spend
Research and development is Intellia Therapeutics, Inc.’s biggest cost line, with R&D expense of about $424 million in 2024. That spend funds discovery, preclinical studies, and platform optimization, and each new gene-editing program needs sustained lab capital before it can advance.
Clinical trial expenses
Clinical trial expenses are Intellia Therapeutics, Inc.’s biggest cost driver: NTLA-2001, NTLA-2002, and other programs require site fees, patient monitoring, data management, and biomarker testing. Rare-disease studies also push cost per patient higher, and Intellia reported research and development spending of about $327 million in 2024, showing how fast trial burn can rise.
Manufacturing and CMC costs
Manufacturing and CMC costs are a key burden for Intellia Therapeutics, Inc. because the Company must make clinical-grade lots, run quality systems, and keep Chemistry, manufacturing, and controls work ready for investigational products. These costs usually rise as programs move from early trials to later-stage studies, when GMP supply, testing, and release work scale up.
Personnel and facilities
Intellia Therapeutics, Inc. keeps a heavy fixed-cost base in personnel and facilities: scientific, clinical, regulatory, and admin staff drive most operating spend, while Cambridge HQ and lab space add steady lease, equipment, and upkeep costs. In 2025, those costs were still anchored by its cash burn profile, with R&D and G&A staying the main expense lines.
That mix makes talent and infrastructure the core cost drivers, so scaling the pipeline depends on hiring speed and lab utilization more than near-term revenue.
- Core costs: staff and labs
- Cambridge HQ adds fixed rent
- R&D and G&A dominate spend
IP, legal, and collaboration management
Intellia Therapeutics, Inc. spends steadily on licensing, patent prosecution, and contract management because genome-editing IP is core to its value. It also pays to maintain and negotiate alliances, since partner terms can shape both R&D scope and future economics.
Protects CRISPR IP and freedom to operate
Funds patents, licenses, and legal work
Supports alliance setup and renewals
Intellia’s Heavy R&D Burn Keeps Costs High
Intellia Therapeutics, Inc.’s cost structure is still driven by research and development, with R&D expense at about $424 million in 2024. Clinical trials, GMP manufacturing, and a fixed Cambridge staff-and-lab base keep cash burn high, while IP and alliance work add steady legal and contract costs.
| Cost line | Latest data | Why it matters |
|---|---|---|
| R&D | About $424 million, 2024 | Main burn driver |
| Staff and labs | Fixed Cambridge base | High overhead |
| IP and alliances | Ongoing legal and contract spend | Protects value |
Revenue Streams
Collaboration revenue
Intellia Therapeutics, Inc. earns most revenue from strategic alliances and co-development deals, with partner funding tied to agreed work plans. In its latest annual filings, collaboration revenue stayed the core top line for a pre-commercial biotech, while product revenue remained $0.
Upfront license and option payments
Intellia Therapeutics, Inc. uses upfront license and option payments as non-dilutive cash from partners for access to its CRISPR tech and program rights. These fees help fund R&D before milestones or royalties kick in; the model fits its 2025 partnership-driven pipeline, where early cash can support costly preclinical and clinical work.
Milestone payments
Milestone payments are a key revenue stream for Intellia Therapeutics, Inc.: partners pay when programs hit technical, clinical, or regulatory steps, and biotech deals often carry total milestone pools in the hundreds of millions of dollars. In 2025, this model still mattered because Intellia’s cash inflows were tied to collaboration progress, not product sales.
Research reimbursement
Research reimbursement is a key part of Intellia Therapeutics, Inc.’s partnered model: some collaboration deals repay shared R&D costs, which helps reduce net spending on co-development work. In Intellia Therapeutics, Inc.’s latest reported year, collaboration revenue was $64.6 million, showing how these reimbursements can cushion pipeline cash burn.
Offsets shared R&D costs
Supports co-development programs
Reduces internal cash outflow
Future product sales and royalties
Intellia Therapeutics, Inc. still has no product sales from approved medicines, so future revenue here would come only if its programs reach market; until then, this stream stays clinical-stage and uncertain. In its latest reported year, Intellia Therapeutics, Inc. recognized collaboration revenue, not commercial product revenue, and any partner royalties would depend on future sales after approval.
- Product revenue starts only after approval
- Partner royalties depend on partner sales
- Still tied to clinical success
Intellia 2025 Revenue: Collaboration Deals Powered All Cash Inflow
In 2025, Intellia Therapeutics, Inc. earned revenue mainly from collaboration agreements, with $64.6 million from partner funding, reimbursements, and milestones. Product revenue was $0, so cash inflow still depended on CRISPR alliance deals, not drug sales.
| Revenue stream | 2025 | Role |
|---|---|---|
| Collaboration revenue | $64.6 million | Main cash source |
| Product revenue | $0 | No approved sales |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.